Hikma launches generic Xeloda in the US

Hikma Pharmaceuticals announced yesterday that its US affiliate West-Ward Pharmaceuticals, has launched a generic version of Genentech’s cancer treatment drug Xeloda (capecitabine) in the US.

The drug, called Capecitabine Tablets, is used to treat patients with colon and metastatic breast cancer.

Said Darwazah, chairman of Hikma, said: “We are very pleased to have this product appro val.”

He added: “We have an excellent pipeline of differentiated products and proven R&D, supply chain and operational capabilities that we expect will drive accelerated and sustainable future growth.”